Ichnos Sciences’ ISB 2001 Receives the US FDA’s Orphan Drug Designation for the Treatment of Multiple Myeloma
Shots:
- The US FDA has granted ODD to ISB 2001 (T-cell engaging trispecific Ab) for the treatment of multiple myeloma
- ISB 2001 showed higher potency in vitro compared to daratumumab + teclistamab which is currently under clinical investigation. The results were presented at AACR 2023
- ISB 2001 demonstrated enhanced tumor cell death in vitro across variable levels of expression of BCMA and CD38 over teclistamab, alnuctamab, and EM-801. Additionally, the company plans to initiate a P-I first-in-human dose-escalation dose-expansion study of ISB 2001, following approval from the HREC in Australia and IND clearance from the US FDA
Ref: PR Newswire | Image: Ichnos Sciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
